Circle Of Life: Raptor Buys Quinsair After Its Return To Original Developer

Quinsair (inhaled levofloxacin) – originally known as Aeroquin – took a circuitous route to its new home at Raptor Pharmaceuticals, which will pay Tripex Pharmaceuticals $68.4m up front and up to $350m in milestone fees plus a small royalty for the cystic fibrosis (CF) drug.